A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
This study is ongoing, but not recruiting participants.
Study NCT01083615
Information provided by OncoGenex Technologies
First Received on February 26, 2010.
Last Updated on February 6, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
